As part of our series focussing on medicines available in Australia, this publication reviews pivotal clinical trial and real-world data supporting the role of encorafenib + binimetinib in the management of advanced BRAF V600E/K-mutated melanoma in Australian clinical practice.
Guiding commentary has been provided by Associate Professor Matteo Carlino, a Medical Oncologist at Westmead and Blacktown Hospitals, a Clinical Associate Professor at The University of Sydney, and faculty member and chair of education at the Melanoma Institute Australia.
Please login below to download this issue (PDF)